Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Major short term milestones

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Oct 24, 2021 4:03pm

126 Views

Post# 34042350

RE:RE:Major short term milestones

What clowns do not realize that the 2 main interim reports are by tetra they wIll release that when they wish. It is to determine to continue the trials or not. If you check the latest management analysis and discussion issues mid October. You can see this discussion already been made so that tells you these two main milestones are going to be very positive and will show superiority of QIXLEEF against opioid

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army